Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Docusign entered its September 3 earnings event with improving IAM adoption, high-single-digit revenue and ARR growth, strong free-cash-flow generation and expanding operating leverage. IAM increased from 10.8% of ARR at January 31, 2026 to 12.6% at April 30, while first-quarter revenue rose 9% and non-GAAP operating margin reached 32.0%. The official investor-relations quote was $64.64 when retrieved. The risk/reward is balanced immediately before results: successful IAM expansion and sustained margin execution support upside, but the latest reported growth benefited from foreign exchange and management still guides to high-single-digit ARR growth.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets18 analysts · as of 18 Aug 2026
Low · most bearish analyst$46.89
Mean target$59.33
High · most bullish analyst$90.00
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$46.8920%

Revenue or ARR growth falls below the prior guidance floor, IAM's share of ARR stalls at or below 12.6%, or product, competitive and infrastructure execution requires heavier spending that pushes margin guidance below 30.5%. In this outcome, the shares could retrace toward the lower portion of the official 52-week trading range.

Base CaseCentral scenario
$59.3356%
Matches the consensus mean

Revenue and ARR growth remain in the high single digits, IAM adoption advances gradually, and fiscal 2027 non-GAAP operating margin remains within the 30.5%-31.0% guidance range. Strong cash generation and repurchases provide support, but growth does not accelerate enough to justify a major re-rating.

Bull CaseUpside scenario
$90.0024%

IAM continues gaining share of ARR beyond 12.6%, fiscal 2027 ARR growth exceeds the 8.25%-8.75% range, and operating margin remains near or above the 32.0% achieved in the first quarter. Broader integrations with major AI and enterprise platforms improve distribution and reinforce Docusign's role across the agreement lifecycle. Under this outcome, the shares could revisit approximately the upper end of the official 52-week trading range.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • IAM adoption is scaling: approximately 40,000 customers were investing in the platform, and IAM represented 12.6% of ARR at April 30, 2026 versus 10.8% three months earlier.
  • Operating execution is strong: first-quarter non-GAAP operating margin was 32.0%, free cash flow was $289.4 million, and common-stock repurchases were $317.5 million.
  • Docusign is extending IAM distribution through integrations with OpenAI, Anthropic, Microsoft, Salesforce, SAP, Slack and other enterprise or legal-AI platforms.
Sign in / Sign up to read more
Key Investment Risks
  • Second-quarter fiscal 2027 results are scheduled for September 3, 2026, creating immediate earnings and guidance-reset risk.
  • First-quarter revenue growth of 9% included an approximately 1.6-percentage-point positive foreign-exchange impact, while fiscal 2027 ARR growth guidance remained 8.25%-8.75%.
  • The company identifies competitive pressure, rapid technological change, AI deployment, cloud migration, cybersecurity, infrastructure reliability and customer-retention execution as material uncertainties.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.